Skip to Content

Improved OS in newly diagnosed multiple myeloma patients not eligible for stem cell transplantation

5-year data from the MAIA study show that the addition of daratumumab to lenalidomide and dexamethasone significantly reduced the risk of death in patients with newly diagnosed multiple myeloma where transplantation is not possible. The risk of death was reduced by 32% compared with lenalidomide and dexamethasone alone.

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Back to top